CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.80 | -$0.54 | Beat |
| May 15, 2026 | -$0.80 | -$0.20 | Beat |
| Feb 25, 2026 | -$0.75 | -$0.75 | Beat |
| Nov 19, 2025 | -$0.76 | -$9.10 | Miss |
| Aug 22, 2025 | -$124.26 | -$61.71 | Beat |
| May 15, 2025 | -$75.50 | -$119.20 | Miss |